Constantiam Biosciences is developing CB-001, a first-in-class oral, CNS-penetrant allosteric chaperone for neuronopathic Gaucher Disease. Underpinning CB-001 is RareScan™, our variant-level drug response prediction platform. Massively-multiplexed functional experiments integrated with probabilistic ML enable smarter candidate nomination, precision trial enrollment, and patient population expansion.